A focus reduction neutralization assay for hepatitis C virus neutralizing antibodies

Area of Science:

• Virology
• Immunology
• Infectious Diseases

Background:

• Humoral immunity's role in Hepatitis C Virus (HCV) infection remains unclear.
• Characterizing neutralizing antibodies in HCV-infected patients is of growing interest.
• Focus reduction assays are established methods for evaluating neutralizing antibody responses.

Purpose of the Study:

• To develop a focus reduction assay for detecting HCV-neutralizing antibodies.
• To utilize a newly developed HCV cell culture system (genotype 2 JFH-1 strain).

Main Methods:

• A standard microneutralization assay format was adapted.
• Immunostained foci on tissue culture plates were counted to determine antibody titers.
• Purified IgG antibodies from 77 individuals were tested using a 50% focus reduction neutralization assay.

Main Results:

• The assay demonstrated 100% specificity and 96.5% sensitivity compared to a commercial HCV ELISA.
• Reproducibility was good, with low intra-assay (6.7%) and inter-assay (12.6%) variations.
• Neutralizing antibody titers were observed for both homologous (2.13 log) and heterologous (1.93 log) samples, indicating broad cross-neutralization.

Conclusions:

• A simple, specific, and reproducible cell culture-based assay for determining HCV-neutralizing antibodies in human sera has been established.
• This assay is a valuable tool for studying the correlation between antibody response and viral load kinetics.
• The assay can aid in investigating the potential for eradicating or preventing HCV infection through neutralizing antibodies.